All In Biotech

Drug Trial Radar · NCT05082259

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Planned (sponsor's estimate)

Start

Mar 2, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Astex Pharmaceuticals, Inc.; Merck Sharp & Dohme LLC; Cancer Research UK
First posted
Oct 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre Phase I dose finding and proof-of-concept study of the combination of ASTX660 together with Pembrolizumab with expansion cohorts testing preliminary efficacy in immune-refractory cancers, triple negative breast cancer (TNBC), cervical cancer, and glioblastoma. In contrast to the existing studies combining first-generation cIAP1/2 selective Smac mimetics with immune check point inhibitors, the ASTEROID Phase I clinical trial will be the first trial utilising triple cIAP1/2 and XIAP blockade by ASTX660 as a strategy to maximise immunogenic cell death and the generation of an efficient adaptive immune response. ASTX660 is not simply being used to repeat the data already being acquired with other first generation Smac mimetics. In contrast, we will investigate more in depth the mechanisms by which ASTX660 elicits its therapeutic effects both on tumour and on the host immune system. This will be critical to determine the best strategy to pursue in future later stage tumour specific trials of IAP antagonists in combination with immunotherapy, and to ensure appropriate molecular stratification biomarkers for the greatest benefit to patients.

Conditions

  • Advanced Cancer
  • Cervical Cancer
  • Triple Negative Breast Cancer

Interventions

  • ASTX660Drug

    ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).

  • PembrolizumabDrug

    Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier. Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of MTD and RP2DTime frame: 12 months
  2. Safety and tolerabilityTime frame: 12 months
  3. Preliminary anti-tumour activity evaluation (in Part B)Time frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cambridge University Hospitals NHS Trust

    Cambridge, United Kingdom

  • The Royal Marden NHS Foundation Trust - Drug Development Unit

    Sutton, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Breast Unit

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.